Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand
Zacks Investment Research | Jan 12, 2021 03:18AM ET
Gilead Sciences (NASDAQ:GILD), Inc. GILD revised its annual guidance for 2020 as the worsening of the coronavirus pandemic drove sales for Veklury (remdesivir).
Total product sales are now projected to come around $24.3-$24.35 billion for 2020, up from the previous guidance of $23-$23.5 billion. The increase in guidance is primarily accountable to increased Veklury sales, as hospitalization and treatment rates were higher than expected, given the most recent COVID-19 surge.
Veklury sales are estimated at $2.8-$2.825 billion.
Total product sales, excluding Veklury, are projected around $21.5-$21.525 billion, indicating the underlying strong Biktarvy uptake, partially offset by the loss of exclusivity of Truvada in the United States and the impact of COVID-19 primarily on Gilead’s pre-exposure prophylaxis (“PrEP”) franchise and chronic hepatitis C virus (“HCV”) franchise.
R&D expenses are now expected to grow 20% (previous guidance: mid-teens percentage growth) to reflect the increase in expenses for obligations under the new commercialization and development agreement for Jyseleca (filgotinib) with Galapagos (NASDAQ:GLPG) NV GLPG . The guidance also reflects higher clinical trial and manufacturing ramp-up expenses related to Gilead’s COVID-19 treatment, remdesivir.
Non-GAAP EPS is now projected at $6.98-$7.08, up from the earlier estimated range of $6.25-$6.60.
Gilead’s shares have lost 2.8% in the past year against the industry ’s growth of 9.7%.
The company was in the spotlight in 2020 primarily due to Veklury, which is approved for the treatment of COVID-19 in the United States and the European Union.
The massive decline in sales of its HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues. Competition is stiffening in the HIV space from the likes of Glaxo GSK .
Hence, Gilead is diversifying into the oncology space. To that end, it acquired Immunomedics (NASDAQ:IMMU) for approximately $21 billion and entered into strategic collaborations to foray into the lucrative oncology space.
Get The News You Want
It has also collaborated with Novo Nordisk (NYSE:NVO) NVO for developing treatments for non-alcoholic steatohepatitis (NASH).
Gilead currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
h3 Looking for Stocks with Skyrocketing Upside?/h3Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.